Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash & Equivalents (2023 - 2025)

Immunome (IMNM) has disclosed Cash & Equivalents for 3 consecutive years, with $653.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 355.86% year-over-year to $653.5 million, compared with a TTM value of $653.5 million through Dec 2025, up 355.86%, and an annual FY2025 reading of $653.5 million, up 355.86% over the prior year.
  • Cash & Equivalents was $653.5 million for Q4 2025 at Immunome, up from $272.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $653.5 million in Q4 2025 and bottomed at $38.4 million in Q2 2023.
  • Average Cash & Equivalents over 3 years is $194.5 million, with a median of $149.7 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents soared 507.16% in 2024, then decreased 12.98% in 2025.
  • Year by year, Cash & Equivalents stood at $98.7 million in 2023, then soared by 45.27% to $143.4 million in 2024, then soared by 355.86% to $653.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for IMNM at $653.5 million in Q4 2025, $272.6 million in Q3 2025, and $143.9 million in Q2 2025.